"Revolutionary DNA Origami Vaccines for Precision Cancer Immunotherapy"
In a groundbreaking discovery by researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, a revolutionary DNA origami platform named DoriVac has been unveiled. This platform utilizes self-assembling nanostructures to deliver precise spacing of adjuvant molecules that stimulate immune cells to produce a robust anti-tumor response.
By attaching adjuvant molecules to a square block-shaped nanostructure, researchers found that spacing these molecules 3.5 nanometers apart yielded the most effective activation of antigen-presenting cells (APCs). These activated APCs then induced a desirable profile of T cells, including cytotoxic T cells that kill cancer cells, Th-1 polarized T cells that cause beneficial inflammation, and memory T cells that provide long-term immune memory of the tumor.
DoriVac vaccines administered to tumor-bearing mice demonstrated enhanced control of tumor growth and significantly increased survival rates compared to control mice. Furthermore, when combined with immune checkpoint inhibitors, a widely used immunotherapy, the effects of DoriVac were amplified, leading to complete regression of melanoma tumors and prevention of regrowth upon re-exposure to tumor cells.
This innovative approach not only shows promising results in preclinical mouse models but also has the potential for personalized cancer vaccines tailored to individual patients. By loading antigens onto prefabricated DNA origami structures, researchers aim to develop highly effective cancer vaccines that can be used in conjunction with existing immunotherapies for improved clinical outcomes.
The implications of this research are far-reaching, offering a new frontier in cancer immunotherapy that leverages nanotechnology to precisely modulate immune responses against tumors. The development of the DoriVac platform represents a significant advancement in the field of precision medicine, bringing us closer to the realization of personalized and effective cancer treatments for patients worldwide.
Source: https://www.eurekalert.org/news-releases/1037728
By attaching adjuvant molecules to a square block-shaped nanostructure, researchers found that spacing these molecules 3.5 nanometers apart yielded the most effective activation of antigen-presenting cells (APCs). These activated APCs then induced a desirable profile of T cells, including cytotoxic T cells that kill cancer cells, Th-1 polarized T cells that cause beneficial inflammation, and memory T cells that provide long-term immune memory of the tumor.
DoriVac vaccines administered to tumor-bearing mice demonstrated enhanced control of tumor growth and significantly increased survival rates compared to control mice. Furthermore, when combined with immune checkpoint inhibitors, a widely used immunotherapy, the effects of DoriVac were amplified, leading to complete regression of melanoma tumors and prevention of regrowth upon re-exposure to tumor cells.
This innovative approach not only shows promising results in preclinical mouse models but also has the potential for personalized cancer vaccines tailored to individual patients. By loading antigens onto prefabricated DNA origami structures, researchers aim to develop highly effective cancer vaccines that can be used in conjunction with existing immunotherapies for improved clinical outcomes.
The implications of this research are far-reaching, offering a new frontier in cancer immunotherapy that leverages nanotechnology to precisely modulate immune responses against tumors. The development of the DoriVac platform represents a significant advancement in the field of precision medicine, bringing us closer to the realization of personalized and effective cancer treatments for patients worldwide.
Source: https://www.eurekalert.org/news-releases/1037728
Comments
Post a Comment